GLI1 and Hypoglycemia: Although pharmacokinetic values were not reported in the studies by Zafardoost et al., or Khalili et al., intermittent oral GLI dosing can be problematic, with sharp supratherapeutic peaks (risking hypoglycemia) and prolonged subtherapeutic troughs [36].